Hypertension (Dallas, Tex. : 1979) · 2026
CD38+ T-Cell Count Is an Immunologic Phenotype Associated With Blood Pressure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Chuan, Xiao Yajuan, Zhou Xin, Zhou Suhan, Abdullah Reema, Chen Jianghua, Han Fei, Ren Pingping, Xiao Liang
Аннотация
BACKGROUND: T lymphocytes play a crucial role in the development of hypertension and associated end-organ damage. CD38 is a well-established surface marker for T-cell activation. However, clinical evidence linking CD38+ T cells, or other specific T-cell subsets, with blood pressure (BP) changes remains limited. We therefore sought to determine whether CD38+ T-cell abundance correlates with BP and whether anti-CD38 therapy influences BP in humans and mice.
METHODS: We performed correlation analyses between peripheral immune cell counts and BP in 197 normotensive and 53 hypertensive subjects. The impact of CD38-targeted therapy on BP was evaluated in multiple myeloma patients (control, n=50; daratumumab, n=27). In addition, we used a murine model of angiotensin II-induced hypertension to characterize T-cell frequency and phenotype in the circulation and kidney by flow cytometry.
RESULTS: Circulating CD38+ T-cell abundance was inversely correlated with BP in both normotensive and hypertensive subjects. This finding was recapitulated in hypertensive mice, which also showed concomitant accumulation of CD38+ T cells in the kidney. In patients, daratumumab-induced depletion of CD38+ cells reduced systolic BP by ≈10 mm Hg for 4 to 6 weeks. This BP-lowering effect was similarly observed in hypertensive mice given an antimurine CD38 antibody.
CONCLUSIONS: Our data identify circulating CD38+ T cells as a novel immunologic biomarker that inversely correlates with BP, potentially reflecting T-cell transmigration during BP elevation.
METHODS: We performed correlation analyses between peripheral immune cell counts and BP in 197 normotensive and 53 hypertensive subjects. The impact of CD38-targeted therapy on BP was evaluated in multiple myeloma patients (control, n=50; daratumumab, n=27). In addition, we used a murine model of angiotensin II-induced hypertension to characterize T-cell frequency and phenotype in the circulation and kidney by flow cytometry.
RESULTS: Circulating CD38+ T-cell abundance was inversely correlated with BP in both normotensive and hypertensive subjects. This finding was recapitulated in hypertensive mice, which also showed concomitant accumulation of CD38+ T cells in the kidney. In patients, daratumumab-induced depletion of CD38+ cells reduced systolic BP by ≈10 mm Hg for 4 to 6 weeks. This BP-lowering effect was similarly observed in hypertensive mice given an antimurine CD38 antibody.
CONCLUSIONS: Our data identify circulating CD38+ T cells as a novel immunologic biomarker that inversely correlates with BP, potentially reflecting T-cell transmigration during BP elevation.